267
Participants
Start Date
December 22, 2015
Primary Completion Date
February 26, 2024
Study Completion Date
February 26, 2024
Tazemetostat
Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
Institut Jules Bordet Medical Oncology Clinic, Brussels
Chris O'Brien Lifehouse, Camperdown
University Hospital Leuven, Leuven
National Taiwan University Hospital, Taipei
Memorial Sloan Kettering Cancer Center, New York
Sarcoma Center HELIOS Klinikum Berlin, Berlin
Instituto Nazionale Tumori - National Cancer Institute Via Giacomo Venezian, Milan
Mayo Clinic - Jacksonville, Jacksonville
Institut Bergonie, Bordeaux
Cincinnati Children's Hospital Medical Center, Cincinnati
University of Michigan, Ann Arbor
Northwestern Memorial Hospital, Chicago
Washington University, St Louis
Centre Leon Berard, Lyon
Institut Curie, Paris
Hospital Pitie Salpetriere, Paris
MD Anderson Cancer Center, Houston
University of Colorado Denver, Aurora
Children's Hospital Augsburg Klinikum, Augsburg
University of California San Francisco, San Francisco
Institut Gustave Roussy, Villejuif
Oregon Health Sciences University, Portland
Seattle Children's Hospital, Seattle
Fred Hutchinson Cancer Research Center, Seattle
Massachusetts General Hospital - Cancer Center, Boston
Dana Farber Cancer Institute, Boston
Metro South Hospital and Health Service via Princess Alexandra Hospital, Woolloongabba
Alberta Health Services, Edmonton
Princess Margaret Hospital, Toronto
McGill University Health Centre - Royal Victoria Hospital, Montreal
University College London Hospital, London
Royal Marsden Foundation Trust, London
Lead Sponsor
Epizyme, Inc.
INDUSTRY